Implantable, self-regulating mechanochemical insulin pump

Claim 2

An implantable pump for the delivery of insulin to a mammal in need thereof, said pump comprising a housing which supports within its walls: (a) an aqueous-swellable member which initiates an insulin pumping cycle by swelling in response to an increase in blood glucose level and terminates an insulin pumping cycle by deswelling in response to a decrease in blood glucose level, said member being exposed to the body fluids which surround the pump when implanted in a mammal; (b) a first chamber containing a pharmaceutically acceptable insulin composition and including a valve means which permits the outflow of the insulin composition; and (c) means coupled with said first chamber for causing insulin to be expelled from the first chamber in response to swelling of the aqueous-swellable member.

Claim 3

A pump according to claim 1 in which the aqueous-swellable member includes immobilized glucose oxidase.

Claim 4

A pump according to claim 1 in which the aqueous-swellable member comprises a pH-sensitive hydrogel membrane which swells in response to a decrease in pH by absorbing aqueous biological fluids.

Claim 5

A pump according to claim 3 in which the aqueous-swellable member includes immobilized glucose oxidase.

Claim 6

A pump according to claim 1 in which the means for causing insulin to be expelled from the first chamber comprises a second chamber.

Claim 7

A pump according to claim 5 in which said second chamber includes a valve means which permits an influx of body fluids as a function of the expulsion of insulin composition from the first chamber.

Claim 8

A pump according to claim 6 in which the second chamber is expandable.

Claim 9

A pump according to claim 1 in which the first chamber is collapsible, such that its internal volume is always substantially the same as the volume of the insulin composition it contains.

Claim 10

A pump according to claim 8 in which the means for causing insulin composition to be expelled from the first chamber comprises a second chamber.

Claim 11

A pump according to claim 9 in which said second chamber includes a valve means which permits an influx of body fluids as a function of the expulsion of insulin composition from the first chamber.

Claim 12

A pump according to claim 10 in which said second chamber is expandable.

Claim 13

A pump according to claim 11 in which said second chamber expands as a function of the expulsion of insulin composition from the first chamber.

Claim 14

A pump according to claim 12 in which the valve means of the first chamber comprises a pressure-responsive valve which permits the outflow of the insulin composition in response to an increase in pressure in the chamber and seals the chamber in response to a decrease in pressure in the chamber.

Claim 15

A pump according to claim 13 in which the valve means of the second chamber comprises a pressure-responsive valve which seals the chamber in response to an increase in pressure in the chamber, and permits an influx of body fluids in response to a decrease in pressure in the chamber.

Claim 16

A pump according to claim 14 in which the aqueous-swellable member comprises a pH-sensitive hydrogel membrane which swells in response to a decrease in pH by absorbing aqueous biological fluids.

Claim 17

A pump according to claim 15 in which the aqueous-swellable member includes immobilized glucose oxidase.

Claim 18

A pump according to claim 1 in which the aqueous-swellable member is a homopolymer or copolymer comprising monomers selected from the group consisting of n-alkyl acrylic acids and methacrylic acids, n-alkyl acrylates and methacrylates, and n-alkylacrylamids and methacrylamides, and the hydroxy- and amino-derivatives thereof.

Claim 19

An implantable pump for the delivery of insulin to a mammal in need thereof, said pump comprising an implantable, biocompatible housing of fixed volume which supports within its walls: (a) an aqueous-swellable hydrogel member which swells in response to an increase in blood glucose level and deswells in response to a decrease in blood glucose level, said member being exposed to the body fluids which surround the pump when implanted in a mammal; (b) means defining a first chamber for holding a pharmaceutically acceptable insulin formulation, including a valve means which permits the outflow of the insulin composition; (c) means defining a second chamber for coupling the swelling of the aqueous-swellable hydrogel member to the first chamber such that insulin composition is expelled from the first chamber in response to swelling of the aqueous-swellable hydrogel member.

Claim 20

An implantable pump for the delivery of insulin to a mammal in need thereof, said pump comprising an implantable, biocompatible housing of fixed volume which supports within its walls: (a) an aqueous-swellable hydrogel member which swells in response to an increase in blood glucose level and deswells in response to a decrease in blood glucose level, said member being exposed to the body fluids which surround the pump when implanted in a mammal; (b) means defining a first chamber for holding a pharmaceutically acceptable insulin formulation, including a valve means which permits the outflow of the insulin composition; (c) means defining a second chamber for coupling the swelling of the aqueous-swellable hydrogel member to the first chamber such that insulin composition is expelled from the first chamber in response to swelling of the aqueous-swellable hydrogel member.

Claim 21

A pump according to claim 18 in which the aqueous-swellable hydrogel member comprises a pH-sensitive hydrogel membrane which swells in response to a decrease in pH by absorbing aqueous biological fluids.

Claim 22

A pump according to claim 19 in which the pH-sensitive hydrogel membrane includes immobilized glucose oxidase.

Claim 23

A pump according to claim 18 in which the first chamber is collapsible, the second chamber is expandable, and the second chamber expands as function of the collapse of the first chamber.

Claim 24

A pump according to claim 21 in which the internal volume of the first chamber decreases as a function of the volume of insulin composition which is expelled.

Claim 25

A pump according to claim 22 in which the total combined volume occupied by the first and second chambers within the housing is always approximately the same when the pressure in both chambers equals the pressure of the environment external to the pump.

Claim 26

A pump according to claim 23 in which the second chamber includes a pressure-responsive valve means which seals the chamber in response to an increase in pressure in the chamber, and permits an influx of body fluids in response to a decrease in pressure in the chamber.

Claim 27

A pump according to claim 24 in which the aqueous-swellable hydrogel member comprises a pH-sensitive hydrogel membrane which swells in response to a decrease in pH by absorbing aqueous biological fluids.

Claim 28

A pump according to claim 25 in which the pH-sensitive hydrogel membrane includes immobilized glucose oxidase.

Claim 29

A pump according to claim 26 in which the influx of body fluids to the second chamber is of a volume approximately equal to the volume of insulin composition expelled from the first chamber.

Claim 30

A pump according to claim 27 in which the aqueous-swellable hydrogel member includes a means adjacent to said hydrogel member and the second chamber for causing an increase in pressure in the second chamber when the hydrogel member swells.

Claim 31

A pump according to claim 28 in which said means for causing an increase in pressure in the second chamber comprises a diaphragm situated between the hydrogel member and the second chamber.

Claim 32

A pump according to claim 29 in which the second chamber comprises an elastomeric bladder.

Claim 33

A pump according to claim 28 which includes a means adjacent to both the first and second chambers whereby an increase in pressure in the second chamber causes an increase in pressure in the first chamber.

Claim 34

A pump according to claim 31 in which said means for causing an increase in pressure in the first chamber comprises a movable partition situated between said first and second chambers.

Claim 35

A pump according to claim 18 in which the aqueous-swellable member is a homopolymer or copolymer comprising monomers selected from the group consisting of n-alkyl acrylic acids and methacrylic acids, n-alkyl acrylates and methacrylates, and n-alkylacrylamids and methacrylamides, and the hydroxy- and amino-derivatives thereof.

Claim 36

An implantable pump for the delivery of insulin to a mammal in need thereof, said pump comprising an implantable, biocompatible housing of fixed volume which supports within its walls: (a) a first chamber containing a pharmaceutically acceptable insulin composition and including a pressure-responsive valve means which permits the outflow of the insulin composition in response to an increase in pressure in the chamber and seals the chamber in response to a decrease in pressure in the chamber; and (b) a second chamber including a pressure-responsive valve means which seals the chamber in response to an increase in pressure in the chamber, and permits an influx of body fluids in response to a decrease in pressure in the chamber; (c) an aqueous-swellable hydrogel member which initiates an insulin pumping cycle by swelling in response to an increase in blood glucose level and terminates an insulin pumping cycle by deswelling in response to a decrease in blood glucose level, said member being exposed to the body fluids which surround the pump when implanted in a mammal and including a coupling means adjacent to at least one of said first and second chambers such that swelling of the hydrogel member causes an increase in pressure in both chambers.

Claim 37

An implantable pump for the delivery of insulin to a mammal in need thereof, said pump comprising an implantable, biocompatible housing of fixed volume which supports within its walls: (a) a first chamber containing a pharmaceutically acceptable insulin composition and including a pressure-responsive valve means which permits the outflow of the insulin composition in response to an increase in pressure in the chamber and seals the chamber in response to a decrease in pressure in the chamber; and (b) a second chamber including a pressure-responsive valve means which seals the chamber in response to an increase in pressure in the chamber, and permits an influx of body fluids in response to a decrease in pressure in the chamber; (c) an aqueous-swellable hydrogel member which initiates an insulin pumping cycle by swelling in response to an increase in blood glucose level and terminates an insulin pumping cycle by deswelling in response to a decrease in blood glucose level, said member being exposed to the body fluids which surround the pump when implanted in a mammal and including a coupling means adjacent to at least one of said first and second chambers such that swelling of the hydrogel member causes an increase in pressure in both chambers.

Claim 38

A pump according to claim 34 in which the pressure-responsive valve in the second chamber permits the influx of body fluids in a volume approximately equal to the volume of insulin composition expelled during each insulin pumping cycle.

Claim 39

A pump according to claim 34 in which the total combined volume occupied by the first and second chambers within the housing is always approximately the same when the pressure in both chambers equals the pressure of the environment external to the pump.

Claim 40

A pump according to claim 34 in which the internal volume of the first chamber is always approximately the same as the volume of the insulin composition it contains.

Claim 41

A pump according to claim 34 in which the aqueous-swellable hydrogel member comprises a pH-sensitive hydrogel membrane.

Claim 42

A pump according to claim 38 in which the aqueous-swellable hydrogel member includes immobilized glucose oxidase.

Claim 43

A pump according to claim 39 in which the aqueous-swellable hydrogel member includes immobilized catalase.

Claim 44

A pump according to claim 39 in which the pH-sensitive hydrogel membrane is a homopolymer or copolymer comprising monomers selected from the group consisting of n-alkyl acrylic acids and methacrylic acids, n-alkyl acrylates and methacrylates, and n-alkylacrylamids and methacrylamides, and the hydroxy and amino- derivatives thereof.

Claim 45

A pump according to claim 41 in which the pH-sensitive hydrogel membrane is a copolymer comprised of AMA or DMA monomers copolymerized with DMA or DMAA monomers.

Claim 46

A pump according to claim 34 in which the aqueous-swellable hydrogel member is a homopolymer or copolymer comprising monomers selected from the group consisting of n-alkyl acrylic acids and methacrylic acids, n-alkyl acrylates and methacrylates, and n-alkylacrylamids and methacrylamides, and the hydroxy and amino- derivatives thereof.

Claim 47

An implantable pump for the self-regulated delivery of insulin to a mammal in need thereof, said pump comprising an implantable, biocompatible housing of fixed volume, which supports within its walls: (a) an aqueous-swellable hydrogel member which initiates an insulin pumping cycle by swelling in response to an increase in blood glucose level and terminates an insulin pumping cycle by deswelling in response to a decrease in blood glucose level, said member being exposed to the body fluids which surround the pump when implanted in a mammal; (b) a first chamber containing a pharmaceutically acceptable insulin composition and including a pressure-responsive valve means which permits the outflow of the insulin composition in response to an increase in pressure in the chamber and seals the chamber in response to a decrease in pressure in the chamber, said chamber being configured such that its internal volume is always the same as the volume of the insulin composition it contains; and (c) a second chamber in intimate contact with said first chamber and in direct or indirect contact with said aqueous-swellable hydrogel member, such that swelling of the hydrogel member due to an increase in blood glucose level causes an increase in pressure in both the first and second chambers, said second chamber including a pressure-responsive valve means which seals the chamber in response to an increase in pressure in the chamber and permits an influx of body fluids in response to a decrease in pressure in the chamber in a volume equal to the volume of insulin composition expelled during each insulin pumping cycle, wherein the total combined volume occupied by the first and second chambers within the housing is always approximately the same when the pressure in both chambers substantially equals the pressure of the environment external to the pump.

Claim 48

An implantable pump for the self-regulated delivery of insulin to a mammal in need thereof, said pump comprising an implantable, biocompatible housing of fixed volume, which supports within its walls: (a) an aqueous-swellable hydrogel member which initiates an insulin pumping cycle by swelling in response to an increase in blood glucose level and terminates an insulin pumping cycle by deswelling in response to a decrease in blood glucose level, said member being exposed to the body fluids which surround the pump when implanted in a mammal; (b) a first chamber containing a pharmaceutically acceptable insulin composition and including a pressure-responsive valve means which permits the outflow of the insulin composition in response to an increase in pressure in the chamber and seals the chamber in response to a decrease in pressure in the chamber, said chamber being configured such that its internal volume is always the same as the volume of the insulin composition it contains; and (c) a second chamber in intimate contact with said first chamber and in direct or indirect contact with said aqueous-swellable hydrogel member, such that swelling of the hydrogel member due to an increase in blood glucose level causes an increase in pressure in both the first and second chambers, said second chamber including a pressure-responsive valve means which seals the chamber in response to an increase in pressure in the chamber and permits an influx of body fluids in response to a decrease in pressure in the chamber in a volume equal to the volume of insulin composition expelled during each insulin pumping cycle, wherein the total combined volume occupied by the first and second chambers within the housing is always approximately the same when the pressure in both chambers substantially equals the pressure of the environment external to the pump.